Adjuvant therapies can be classified according to identified tumor subtypes; for example, escalation therapy specifically targets human epidermal growth factor receptor 2 (HER-2) in patients with HER-2-positive breast cancer [9]. The gene discussed is ERBB2; the disease is breast carcinoma.